With a FDA phase 3 trial succeeding, there is a partner there 100% if they wanted it.
Financially it would mean giving up future cash flows, so SI will need to figure out the best path forward for shareholders. Do another cap raise (at a reasonable price) before partnering CHF, lower back pain... or partner pediatric aGVHD resolve the short term cash problem but give away future cash flows.
This is a long term investment, irrational decisions now can have a significant detrimental effect to the long term value of MSB.
More importantly though, the technology is being validated in FDA phase 3 clinical trials. MSB’s MSC technology is no longer a “dream”, it is now becoming reality. 2018 milestone year.
NIH sponsored 2b CHF LVAD trial up next.
-
- There are more pages in this discussion • 237 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
